Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Borlaug, BA; Kitzman, DW; Davies, MJ; Rasmussen, S; Barros, E; Butler, J; Einfeldt, MN; Hovingh, GK; Moller, DV; Petrie, MC; Shah, SJ; Verma, S; Abhayaratna, W; Ahmed, FZ; Chopra, V; Ezekowitz, J; Fu, MC; Ito, H; Lelonek, M; Melenovsky, V; Núñez, J; Perna, E; Schou, M; Senni, M; van der Meer, P; Von Lewinski, D; Wolf, D; Kosiborod, MN

Kosiborod, MN (通讯作者)，Univ Missouri, St Lukes Mid Amer Heart Inst, Sch Med, Dept Cardiovasc Dis, Kansas City, MO 65211 USA.

NATURE MEDICINE, 2023; 29 (9): 2358

Abstract

In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity ph......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索